The potential distraction of a pan-regimen approach to tuberculosis

In the past decade, the tuberculosis therapeutic landscape has been transformed, with novel tuberculosis drugs and strategies promising shorter, safer, and more tolerable therapy for the millions of individuals who become sick with tuberculosis annually.1 As tuberculosis research continues to progress, consensus around target regimens is needed to guide research and investment. Instead of the personalised, precision medicine characterising therapeutic innovations in other fields,2 the tuberculosis research community is seeking solutions by aiming to offer everyone with tuberculosis the same treatment.